1197377-31-3Relevant articles and documents
Deuterated Capmatinib compounds and uses thereof
-
, (2019/12/25)
The invention discloses deuterated Capmatinib compounds and uses thereof, in particular to compounds represented by formula (I) or optical isomers, pharmaceutically acceptable salts, hydrate or solvate thereof, wherein R1-R16 is independently selected fro
Design, synthesis, and biological evaluation of novel imidazo[1,2-a]pyridine derivatives as potent c-met inhibitors
Li, Chunpu,Ai, Jing,Zhang, Dengyou,Peng, Xia,Chen, Xi,Gao, Zhiwei,Su, Yi,Zhu, Wei,Ji, Yinchun,Chen, Xiaoyan,Geng, Meiyu,Liu, Hong
, p. 507 - 512 (2015/05/27)
A series of imidazo[1,2-a]pyridine derivatives against c-Met was designed by means of bioisosteric replacement. In this study, a selective, potent c-Met inhibitor, 22e was identified, with IC50 values of 3.9 nM against c-Met kinase and 45.0 nM
IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS
-
, (2011/09/20)
The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME
-
Page/Page column 22; 23-24, (2009/12/05)
The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.